Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

185.01 +2.40 (+1.32%)

Streaming Delayed Price Updated: 10:17 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack

October 01, 2025

Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns

October 01, 2025

Boston, MA – October 1, 2025 – Biogen Inc. (NASDAQ: BIIB) saw its stock surge by an impressive 9.02% today, propelled by a wave of promising advancements in its Alzheimer's disease drug testing...

Via MarketMinute

Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years ↗

October 01, 2025

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.

Via Benzinga

Topics Government

A Look Into Biogen Inc's Price Over Earnings ↗

September 18, 2025

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

September 11, 2025

Via Benzinga

Wednesday's session: top gainers and losers in the S&P500 index ↗

October 01, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Via Chartmill

Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗

October 01, 2025

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.

Via Benzinga

Which S&P500 stocks are moving on Wednesday? ↗

October 01, 2025

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Dow Futures Defy Shutdown Fears: A Deep Dive into Market Resilience

September 29, 2025

As the U.S. government teeters on the brink of another shutdown, a seemingly counter-intuitive phenomenon is gripping financial markets: Dow futures are not only holding steady but are showing signs of...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

September 28, 2025

From Biogen Inc.

Via GlobeNewswire

Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays

September 27, 2025

Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29,...

Via MarketMinute

Topics Artificial Intelligence Earnings

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy ↗

September 25, 2025

On Tuesday, the U.S.

Via Benzinga

This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

What 6 Analyst Ratings Have To Say About Biogen ↗

September 24, 2025

Via Benzinga

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

September 24, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

September 23, 2025

From Biogen Inc.

Via GlobeNewswire

Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

September 22, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex...

Via StockStory

Topics Artificial Intelligence

Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment ↗

September 18, 2025

Biogen will integrate Alcyone's team and divest the remaining assets into Neela Therapeutics as part of its $85 million acquisition.

Via Benzinga

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

September 18, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

September 17, 2025

From Biogen Inc.

Via GlobeNewswire

Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way

September 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen...

Via StockStory

Topics Artificial Intelligence

Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)

September 15, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical...

Via StockStory

Topics Artificial Intelligence

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 That Underwhelm

September 08, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Economy

Biogen (BIIB) Stock Trades Down, Here Is Why

September 04, 2025

Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the...

Via StockStory

Topics Artificial Intelligence

Beyond The Numbers: 10 Analysts Discuss Biogen Stock ↗

September 04, 2025

Via Benzinga

Market Monitor News September 3 BMO - Tech Slammed, Yields Spike, Trump Stirring the Pot Again ↗

September 03, 2025

Wall Street kicked off September on shaky ground as rising bond yields pressured tech stocks and legal turmoil over Trump’s tariffs added fresh uncertainty. Meanwhile, investors brace for Friday’s key...

Via Chartmill

Topics Bonds Economy Government

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

September 02, 2025

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive,...

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.